Market Overview

Is Allergan Worth Over $300 Without Pfizer?

Is Allergan Worth Over $300 Without Pfizer?

Allergan plc Ordinary Shares (NYSE: AGN) plummeted this week as news broke that Pfizer Inc. (NYSE: PFE) and Allergan will be terminating their proposed merger. The stock may have taken a hit, but a pair of Wall Street analysts believe that there’s plenty of value in a stand-alone Allergan.

Deutsche Bank’s Gregg Gilbert recently set a standalone target price of $282 for Allergan, even though the company now faces a pair of short-term headwinds associated with the terminated deal. First, Allergan’ employees have likely been understandably distracted and concerned about the potential deal, and the company’s workforce production has likely suffered.

Related Link: Allergan Now Trades Cheaper Than Its Standalone Value

“With investor sentiment at poor levels for the space, and the natural skepticism that may follow when a company had agreed to sell itself, some investors may take a more wait-and-see approach,” Gilbert adds.

Deutsche Bank maintains a Buy rating on Allergan.

Citi analyst Liav Abraham believes Allergan will now go right back to prior focus on fundamentals.

“Over the near term, we expect the cost cutting recently excluded from estimates pending the closure of the PFE/AGN transaction to be re-implemented,” Abraham notes.

Citi is even more bullish on the standalone stock that Deutsche Bank and maintains a Buy rating and $360 price target.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for PFE

Oct 2019ReinstatesNeutral
Aug 2019UpgradesSellHold
Aug 2019MaintainsEqual-Weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Citi Deutsche Bank Gregg Gilbert Liav AbrahamAnalyst Color Biotech Analyst Ratings General Best of Benzinga


Related Articles (AGN + PFE)

View Comments and Join the Discussion!

Latest Ratings

ROSTMKM PartnersMaintains121.0
BJDeutsche BankMaintains27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: U.S. Stocks Rise; Cree Shares Decline On Weak Outlook

Financial Services Confirms Receipt Of Notice From Activist Investor, Touts Shareholder Return